1
|
Hermida A, Ader F, Millat G, Jedraszak G, Maury P, Cador R, Catalan PA, Clerici G, Combes N, De Groote P, Dupin-Deguine D, Eschalier R, Faivre L, Garcia P, Guillon B, Janin A, Kugener B, Lackmy M, Laredo M, Le Guillou X, Lesaffre F, Lucron H, Milhem A, Nadeau G, Nguyen K, Palmyre A, Perdreau E, Picard F, Rebotier N, Richard P, Rooryck C, Seitz J, Verloes A, Vernier A, Winum P, Yabeta GAD, Bouchot O, Chevalier P, Charron P, Gandjbakhch E. NEXN Gene in Cardiomyopathies and Sudden Cardiac Deaths: Prevalence, Phenotypic Expression, and Prognosis. Circ Genom Precis Med 2024; 17:e004285. [PMID: 38059363 DOI: 10.1161/circgen.123.004285] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/14/2023] [Accepted: 11/05/2023] [Indexed: 12/08/2023]
Abstract
BACKGROUND Few clinical data are available on NEXN mutation carriers, and the gene's involvement in cardiomyopathies or sudden death has not been fully established. Our objectives were to assess the prevalence of putative pathogenic variants in NEXN and to describe the phenotype and prognosis of patients carrying the variants. METHODS DNA samples from consecutive patients with cardiomyopathy or sudden cardiac death/sudden infant death syndrome/idiopathic ventricular fibrillation were sequenced with a custom panel of genes. Index cases carrying at least one putative pathogenic variant in the NEXN gene were selected. RESULTS Of the 9516 index patients sequenced, 31 were carriers of a putative pathogenic variant in NEXN only, including 2 with double variants and 29 with a single variant. Of the 29 unrelated probands with a single variant (16 males; median age at diagnosis, 32.0 [26.0-49.0] years), 21 presented with dilated cardiomyopathy (prevalence, 0.33%), and 3 presented with hypertrophic cardiomyopathy (prevalence, 0.14%). Three patients had idiopathic ventricular fibrillation, and there were 2 cases of sudden infant death syndrome (prevalence, 0.46%). For patients with dilated cardiomyopathy, the median left ventricle ejection fraction was 37.5% (26.25-50.0) at diagnosis and improved with treatment in 13 (61.9%). Over a median follow-up period of 6.0 years, we recorded 3 severe arrhythmic events and 2 severe hemodynamic events. CONCLUSIONS Putative pathogenic NEXN variants were mainly associated with dilated cardiomyopathy; in these individuals, the prognosis appeared to be relatively good. However, severe and early onset phenotypes were also observed-especially in patients with double NEXN variants. We also detected NEXN variants in patients with hypertrophic cardiomyopathy and sudden infant death syndrome/idiopathic ventricular fibrillation, although a causal link could not be established.
Collapse
Affiliation(s)
- Alexis Hermida
- Cardiology, Arrhythmia, and Cardiac Stimulation Service (A.H.), Amiens-Picardie University Hospital
- EA4666 HEMATIM, University of Picardie-Jules Verne, Amiens (A.H., G.J.)
- Institute of Cardiology and ICAN Institute for Cardiometabolism and Nutrition (A.H., M. Laredo, P. Charron, E.G.)
- Department of Genetics, Department of Cardiology, and Referral center for hereditary cardiac diseases, APHP, Pitié-Salpêtrière Hospital (A.H., P. Charron, E.G.)
| | - Flavie Ader
- Unité Pédagogique de Biochimie, Département des Sciences Biologiques et Médicales, UFR de Pharmacie-Faculté de Santé, Université Paris Cité (F.A.)
- Unité Fonctionnelle de Cardiogénétique et Myogénétique Moléculaire et Cellulaire, DMU Biogem, Service de Biochimie Métabolique, AP-HP-Sorbonne Université, Pitié-Salpêtrière -Charles Foix (F.A., P.R.)
- Sorbonne Université, INSERM 1166, Paris (F.A., M. Laredo, P.R., P. Charron, E.G.)
| | - Gilles Millat
- Service de Génétique Moléculaire, Hospices Civils de Lyon (G.M., A.J.)
| | - Guillaume Jedraszak
- Molecular Genetics Laboratory (G.J.), Amiens-Picardie University Hospital
- EA4666 HEMATIM, University of Picardie-Jules Verne, Amiens (A.H., G.J.)
| | | | - Romain Cador
- Service de Cardiologie, Hôpital Saint Joseph, Paris (R.C.)
| | | | - Gaël Clerici
- Service de Cardiologie, Centre hospitalier universitaire, Saint Pierre, La Réunion (G.C.)
| | - Nicolas Combes
- Service de Cardiologie, Clinique Pasteur, Toulouse (N.C.)
| | - Pascal De Groote
- France CHU Lille, Service de Cardiologie & Inserm U1167, Institut Pasteur de Lille (P.D.G.)
| | | | | | | | - Patricia Garcia
- Unité Mort Inattendue du Nourrisson, Hôpital de la Conception, APHM, Marseille (P.G.)
| | | | - Alexandre Janin
- Service de Génétique Moléculaire, Hospices Civils de Lyon (G.M., A.J.)
| | | | - Marylin Lackmy
- Unité de Génétique Clinique, CHU de Guadeloupe, Pointe à Pitre (M. Lackmy)
| | - Mikael Laredo
- Institute of Cardiology and ICAN Institute for Cardiometabolism and Nutrition (A.H., M. Laredo, P. Charron, E.G.)
- Sorbonne Université, INSERM 1166, Paris (F.A., M. Laredo, P.R., P. Charron, E.G.)
| | | | | | - Hugues Lucron
- Service de Cardiologie pédiatrique, CHU Martinique, Fort-de-France (H.L.)
| | | | - Gwenaël Nadeau
- Service de génétique clinique CH Métropole Savoie, Chambéry (G.N.)
| | | | - Aurélien Palmyre
- APHP, Ambroise Paré Hospital, Department of Genetics and Referral center for cardiac hereditary cardiac diseases, Boulogne-Billancourt (A.P., P. Charron)
| | - Elodie Perdreau
- Département médico chirurgical de cardiologie pédiatrique (E.P.), Hôpital Louis Pradel, HCL, Lyon
| | - François Picard
- Service de Cardiologie, Hôpital Cardiologique Haut Leveque, Bordeaux (F.P.)
| | | | - Pascale Richard
- Unité Fonctionnelle de Cardiogénétique et Myogénétique Moléculaire et Cellulaire, DMU Biogem, Service de Biochimie Métabolique, AP-HP-Sorbonne Université, Pitié-Salpêtrière -Charles Foix (F.A., P.R.)
- Sorbonne Université, INSERM 1166, Paris (F.A., M. Laredo, P.R., P. Charron, E.G.)
| | | | - Julien Seitz
- Service de Cardiologie, Hôpital Saint Joseph, Marseille (J.S.)
| | - Alain Verloes
- Departement de génétique, Hôpital Robert Debré, APHP (A. Verloes)
| | | | | | - Grace-A-Dieu Yabeta
- Service de Cardiologie, CH Ouest Guyane, Saint-Laurent-du-Maroni (G.-A.-D.Y.)
| | - Océane Bouchot
- Service de Cardiologie, CH Annecy Genevois, Annecy, France (O.B.)
| | | | - Philippe Charron
- Institute of Cardiology and ICAN Institute for Cardiometabolism and Nutrition (A.H., M. Laredo, P. Charron, E.G.)
- Department of Genetics, Department of Cardiology, and Referral center for hereditary cardiac diseases, APHP, Pitié-Salpêtrière Hospital (A.H., P. Charron, E.G.)
- Sorbonne Université, INSERM 1166, Paris (F.A., M. Laredo, P.R., P. Charron, E.G.)
- APHP, Ambroise Paré Hospital, Department of Genetics and Referral center for cardiac hereditary cardiac diseases, Boulogne-Billancourt (A.P., P. Charron)
| | - Estelle Gandjbakhch
- Institute of Cardiology and ICAN Institute for Cardiometabolism and Nutrition (A.H., M. Laredo, P. Charron, E.G.)
- Department of Genetics, Department of Cardiology, and Referral center for hereditary cardiac diseases, APHP, Pitié-Salpêtrière Hospital (A.H., P. Charron, E.G.)
- Sorbonne Université, INSERM 1166, Paris (F.A., M. Laredo, P.R., P. Charron, E.G.)
| |
Collapse
|
2
|
Gallois Y, Siegfried A, Dupin-Deguine D, Deguine O. Bilateral tympanic myxoma: A CARE case report. Eur Ann Otorhinolaryngol Head Neck Dis 2023; 140:43-45. [PMID: 36333210 DOI: 10.1016/j.anorl.2022.10.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
INTRODUCTION Ear myxoma is a rare benign tumor sometimes located on the pinna and the external auditory meatus, associated with Carney Complex (CNC). However, tympanic membrane myxoma has never been described. We present here a case of bilateral tympanic membrane myxoma, following CARE guidelines. OBSERVATION A 35-year-old woman presented to our department with right otalgia. Otoscopy showed non-specific bilateral tissular masses in the posterior quadrant of the tympanic membranes, with normal hearing thresholds. CT-scan showed a tissular mass without osteolysis. Right-side resection confirmed the lesion as being a myxoma, ruling out differential diagnoses. The patient was then screened for extra-otologic lesions typically associated with ear myxoma in CNC. Only perilabial lesions similar to lentigos suggested CNC. Cardiac, endocrine and thyroid assessment were normal. Genetic testing for a PKRAR1A gene mutation was negative. DISCUSSION This is to our knowledge the first reported case of tympanic membrane myxoma. It is of particular interest, being bilateral and showing spontaneous involution of the left lesion over the years. Genetic screening was negative; nevertheless, thorough evaluation is essential due to the life-threatening nature of cardiac myxoma and the frequently associated malignant tumors. Potential new mutations associated with CNC should be considered in the future.
Collapse
Affiliation(s)
- Y Gallois
- Service d'ORL, otoneurologie et ORL pédiatrique (Otoneurology and Pediatric ENT Department), hôpital Pierre-Paul-Riquet, CHU de Toulouse Purpan, Toulouse, France; Université Toulouse 3-Paul-Sabatier, Toulouse, France.
| | - A Siegfried
- Département d'anatomie et cytologie pathologiques, institut universitaire du cancer Toulouse-Oncopole, CHU de Toulouse, Toulouse, France
| | - D Dupin-Deguine
- Service d'ORL, otoneurologie et ORL pédiatrique (Otoneurology and Pediatric ENT Department), hôpital Pierre-Paul-Riquet, CHU de Toulouse Purpan, Toulouse, France; Service de génétique clinique (Clinical Genetics Department), hôpital Pierre-Paul-Riquet, CHU de Toulouse, Toulouse, France
| | - O Deguine
- Service d'ORL, otoneurologie et ORL pédiatrique (Otoneurology and Pediatric ENT Department), hôpital Pierre-Paul-Riquet, CHU de Toulouse Purpan, Toulouse, France; Université Toulouse 3-Paul-Sabatier, Toulouse, France
| |
Collapse
|
3
|
Legoupil S, Bessis D, Picard F, Mallet S, Mazereeuw J, Phan A, Dupin-Deguine D, Kalamarides M, Chiaverini C. Dermatologic manifestations in paediatric neurofibromatosis type 2: a cross sectional descriptive multicentric study. Orphanet J Rare Dis 2022; 17:242. [PMID: 35729665 PMCID: PMC9210598 DOI: 10.1186/s13023-022-02379-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2022] [Accepted: 06/06/2022] [Indexed: 11/27/2022] Open
Abstract
Background Neurofibromatosis type 2 (NF2) is characterized by bilateral vestibular schwannoma (VS) more often in adults but a severe paediatric form with multiple neurological tumours is also described. In this population, a early diagnosis is important to prevent the onset of neurological complications but is difficult, particularly without a familial history. Cutaneous manifestations, which may precede VS or neurological tumours by several years, may contribute to an early diagnosis, but specific studies are lacking. The objective of this study was to characterize cutaneous manifestations of NF2 in a paediatric population. Results This observational, descriptive and multicentric study was conducted from April 2019 to April 2020 in seven academic French hospitals. We included patients ≤ 18 years old who fulfilled the Manchester diagnostic criteria or had a pathogenic mutation identified in the NF2 gene. All patients underwent a dermatological examination guided by a standardized questionnaire. 21 children were included, of whom 20 had at least one skin tumour (mean number 5 ± 4.6 [range 0–15]), which led to a diagnosis in four cases. In the other 17 cases, the diagnosis of NF2 was based on neurosensory complications (n = 10), family screening (n = 4) or ocular signs (n = 3). Before the NF2 diagnosis, 15 children had at least one “undiagnosed” cutaneous tumour that did not lead to a specific management. Patients’ dermatological examination also revealed < 6 non specific café au lait macules (n = 15), hypopigmented macules (n = 12) with more than 3 lesions in 4 cases, and purple reticulated macules of the trunk (n = 4). Conclusion Dermatological lesions are frequent and early in children with NF2 but rarely lead to the diagnosis. Cutaneous schwannomas are the most frequent but are often underdiagnosed. Café au lait macules are frequent, but atypical and mostly in small numbers. Multiple hypopigmented macules seem suggestive although inconsistent. The sensitivity of reticulated capillary malformation-like lesions remains to be assessed by further studies. Supplementary Information The online version contains supplementary material available at 10.1186/s13023-022-02379-6.
Collapse
Affiliation(s)
- S Legoupil
- Department of Dermatology, CRMRP-Sud, ARCHET 2 Hospital, CHU de Nice, 151 route st Antoine de Ginestière, 06200, Nice, France.,Department of Pediatrics, CHU de Nice, Fondation Lenval, Nice, France
| | - D Bessis
- Department of Dermatology, CHU de Montpellier, Montpellier, France
| | - F Picard
- Department of Dermatology, CHU de Bordeaux, Bordeaux, France
| | - S Mallet
- Department of Dermatology, APHM, Timone Enfant de Marseille, Marseille, France
| | - J Mazereeuw
- Department of Dermatology, CHU de Toulouse, Toulouse, France
| | - A Phan
- Department of Pediatric Dermatology, Hospices Civils de Lyon, Lyon, France
| | | | - M Kalamarides
- Department of Neurosurgery, APHP, Pitié-Salpêtrière, Paris, France.,CNR-NF2, APHP, Pitié-Salpêtrière, Paris, France
| | | | - C Chiaverini
- Department of Dermatology, CRMRP-Sud, ARCHET 2 Hospital, CHU de Nice, 151 route st Antoine de Ginestière, 06200, Nice, France. .,Department of Pediatrics, CHU de Nice, Fondation Lenval, Nice, France.
| |
Collapse
|
4
|
Chesneau B, Aubert-Mucca M, Fremont F, Pechmeja J, Soler V, Isidor B, Nizon M, Dollfus H, Kaplan J, Fares-Taie L, Rozet JM, Busa T, Lacombe D, Naudion S, Amiel J, Rio M, Attie-Bitach T, Lesage C, Thouvenin D, Odent S, Morel G, Vincent-Delorme C, Boute O, Vanlerberghe C, Dieux A, Boussion S, Faivre L, Pinson L, Laffargue F, Le Guyader G, Le Meur G, Prieur F, Lambert V, Laudier B, Cottereau E, Ayuso C, Corton-Pérez M, Bouneau L, Le Caignec C, Gaston V, Jeanton-Scaramouche C, Dupin-Deguine D, Calvas P, Chassaing N, Plaisancié J. First evidence of SOX2 mutations in Peters' anomaly: lessons from molecular screening of 95 patients. Clin Genet 2022; 101:494-506. [PMID: 35170016 DOI: 10.1111/cge.14123] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2021] [Revised: 02/10/2022] [Accepted: 02/12/2022] [Indexed: 11/30/2022]
Abstract
Peters' anomaly (PA) is a rare anterior segment dysgenesis characterized by central corneal opacity and irido-lenticulo-corneal adhesions. Several genes are involved in syndromic or isolated PA (B3GLCT, PAX6, PITX3, FOXE3, CYP1B1). Some Copy Number Variations (CNVs) have also been occasionally reported. Despite this genetic heterogeneity, most of patients remain without genetic diagnosis. We retrieved a cohort of 95 individuals with PA and performed genotyping using a combination of Comparative genomic hybridization, whole genome, exome and targeted sequencing of 119 genes associated with ocular development anomalies. Causative genetic defects involving 12 genes and CNVs were identified for 1/3 of patients. Unsurprisingly, B3GLCT and PAX6 were the most frequently implicated genes, respectively in syndromic and isolated PA. Unexpectedly, the third gene involved in our cohort was SOX2, the major gene of micro-anophthalmia. Four unrelated patients with PA (isolated or with microphthalmia) were carrying pathogenic variants in this gene that was never associated with PA before. Here we described the largest cohort of PA patients ever reported. The genetic bases of PA are still to be explored as genetic diagnosis was unavailable for 2/3 of patients. Nevertheless, we showed here for the first time the involvement of SOX2 in PA, offering new evidence for its role in corneal transparency and anterior segment development. This article is protected by copyright. All rights reserved.
Collapse
Affiliation(s)
- Bertrand Chesneau
- Génétique Médicale, Hôpital Purpan, CHU, Toulouse, France.,Centre de Référence pour les Affections Rares en Génétique Ophtalmologique (CARGO), CHU, Toulouse, France
| | | | - Félix Fremont
- Centre de Référence pour les Affections Rares en Génétique Ophtalmologique (CARGO), CHU, Toulouse, France.,Service d'ophtalmologie, Hôpital Purpan, CHU Toulouse, France
| | - Jacmine Pechmeja
- Centre de Référence pour les Affections Rares en Génétique Ophtalmologique (CARGO), CHU, Toulouse, France.,Service d'ophtalmologie, Hôpital Purpan, CHU Toulouse, France
| | - Vincent Soler
- Centre de Référence pour les Affections Rares en Génétique Ophtalmologique (CARGO), CHU, Toulouse, France.,Service d'ophtalmologie, Hôpital Purpan, CHU Toulouse, France
| | - Bertrand Isidor
- Génétique Médicale, Institut du thorax, INSERM, CNRS, UNIV Nantes, Nantes, France
| | - Mathilde Nizon
- Génétique Médicale, Institut du thorax, INSERM, CNRS, UNIV Nantes, Nantes, France
| | - Hélène Dollfus
- Centre de Référence pour les Affections Rares en Génétique Ophtalmologique (CARGO), Hôpitaux Universitaires, Strasbourg, France
| | - Josseline Kaplan
- Laboratoire de Génétique Ophtalmologique, INSERM U1163, Institut Imagine, Paris, France
| | - Lucas Fares-Taie
- Laboratoire de Génétique Ophtalmologique, INSERM U1163, Institut Imagine, Paris, France
| | - Jean-Michel Rozet
- Laboratoire de Génétique Ophtalmologique, INSERM U1163, Institut Imagine, Paris, France
| | - Tiffany Busa
- Génétique Clinique, AP- HM CHU Timone Enfants, Marseille, France
| | - Didier Lacombe
- Département de Génétique Médicale, CHU Bordeaux, Bordeaux, France
| | - Sophie Naudion
- Département de Génétique Médicale, CHU Bordeaux, Bordeaux, France
| | - Jeanne Amiel
- Service de Génétique Médicale, Hôpital Necker-Enfants Malades, AP-HP, Paris, France
| | - Marlène Rio
- Service de Génétique Médicale, Hôpital Necker-Enfants Malades, AP-HP, Paris, France
| | - Tania Attie-Bitach
- Service d'Histologie-Embryologie-Cytogénétique, Hôpital Necker-Enfants Malades, AP-, HP, Paris, France
| | | | | | - Sylvie Odent
- Service de Génétique Clinique, Centre Labellisé pour les Anomalies du Développement Ouest, CHU Rennes; Institut de Génétique et Développement de Rennes, CNRS, UMR 6290, Université de Rennes, ERN ITHACA, France
| | - Godelieve Morel
- Service de Génétique Clinique, Centre Labellisé pour les Anomalies du Développement Ouest, CHU Rennes; Institut de Génétique et Développement de Rennes, CNRS, UMR 6290, Université de Rennes, ERN ITHACA, France
| | | | | | | | | | | | - Laurence Faivre
- Centre de Référence Anomalies du Développement et Syndromes Malformatifs, FHU TRANSLAD, CHU, Dijon, France
| | - Lucile Pinson
- Département de Génétique Médicale, Maladies Rares et Médecine Personnalisée, CHU de Montpellier, France
| | | | | | | | | | - Victor Lambert
- Service d'ophtalmologie, Hôpital Nord, Saint-Etienne, France
| | | | | | - Carmen Ayuso
- Genetics & Genomics Department, Jiménez Díaz University Hospital-Universidad Autónoma de Madrid (IIS-FJD-UAM). Centre for Biomedical Network Research on Rare Diseases (CIBERER), Madrid, Spain
| | - Marta Corton-Pérez
- Genetics & Genomics Department, Jiménez Díaz University Hospital-Universidad Autónoma de Madrid (IIS-FJD-UAM). Centre for Biomedical Network Research on Rare Diseases (CIBERER), Madrid, Spain
| | | | | | | | | | | | - Patrick Calvas
- Génétique Médicale, Hôpital Purpan, CHU, Toulouse, France.,Centre de Référence pour les Affections Rares en Génétique Ophtalmologique (CARGO), CHU, Toulouse, France
| | - Nicolas Chassaing
- Génétique Médicale, Hôpital Purpan, CHU, Toulouse, France.,Centre de Référence pour les Affections Rares en Génétique Ophtalmologique (CARGO), CHU, Toulouse, France
| | - Julie Plaisancié
- Génétique Médicale, Hôpital Purpan, CHU, Toulouse, France.,Centre de Référence pour les Affections Rares en Génétique Ophtalmologique (CARGO), CHU, Toulouse, France.,INSERM U1214, ToNIC, Université Toulouse III, France
| |
Collapse
|
5
|
Mansard L, Baux D, Vaché C, Blanchet C, Meunier I, Willems M, Faugère V, Baudoin C, Moclyn M, Bianchi J, Dollfus H, Gilbert-Dussardier B, Dupin-Deguine D, Bonneau D, Drumare I, Odent S, Zanlonghi X, Claustres M, Koenig M, Kalatzis V, Roux AF. The Study of a 231 French Patient Cohort Significantly Extends the Mutational Spectrum of the Two Major Usher Genes MYO7A and USH2A. Int J Mol Sci 2021; 22:ijms222413294. [PMID: 34948090 PMCID: PMC8703989 DOI: 10.3390/ijms222413294] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2021] [Revised: 12/03/2021] [Accepted: 12/08/2021] [Indexed: 01/06/2023] Open
Abstract
Usher syndrome is an autosomal recessive disorder characterized by congenital hearing loss combined with retinitis pigmentosa, and in some cases, vestibular areflexia. Three clinical subtypes are distinguished, and MYO7A and USH2A represent the two major causal genes involved in Usher type I, the most severe form, and type II, the most frequent form, respectively. Massively parallel sequencing was performed on a cohort of patients in the context of a molecular diagnosis to confirm clinical suspicion of Usher syndrome. We report here 231 pathogenic MYO7A and USH2A genotypes identified in 73 Usher type I and 158 Usher type II patients. Furthermore, we present the ACMG classification of the variants, which comprise all types. Among them, 68 have not been previously reported in the literature, including 12 missense and 16 splice variants. We also report a new deep intronic variant in USH2A. Despite the important number of molecular studies published on these two genes, we show that during the course of routine genetic diagnosis, undescribed variants continue to be identified at a high rate. This is particularly pertinent in the current era, where therapeutic strategies based on DNA or RNA technologies are being developed.
Collapse
Affiliation(s)
- Luke Mansard
- Molecular Genetics Laboratory, University of Montpellier, CHU Montpellier, F-34000 Montpellier, France; (L.M.); (D.B.); (C.V.); (V.F.); (C.B.); (M.M.); (J.B.); (M.C.); (M.K.)
| | - David Baux
- Molecular Genetics Laboratory, University of Montpellier, CHU Montpellier, F-34000 Montpellier, France; (L.M.); (D.B.); (C.V.); (V.F.); (C.B.); (M.M.); (J.B.); (M.C.); (M.K.)
- Institute for Neurosciences of Montpellier (INM), University of Montpellier, Inserm, F-34000 Montpellier, France; (I.M.); (M.W.); (V.K.)
| | - Christel Vaché
- Molecular Genetics Laboratory, University of Montpellier, CHU Montpellier, F-34000 Montpellier, France; (L.M.); (D.B.); (C.V.); (V.F.); (C.B.); (M.M.); (J.B.); (M.C.); (M.K.)
- Institute for Neurosciences of Montpellier (INM), University of Montpellier, Inserm, F-34000 Montpellier, France; (I.M.); (M.W.); (V.K.)
| | - Catherine Blanchet
- National Reference Centre for Inherited Sensory Diseases, University Montpellier, CHU Montpellier, F-34000 Montpellier, France;
- Oto Laryngology Department, University of Montpellier, CHU Montpellier, F-34000 Montpellier, France
| | - Isabelle Meunier
- Institute for Neurosciences of Montpellier (INM), University of Montpellier, Inserm, F-34000 Montpellier, France; (I.M.); (M.W.); (V.K.)
- National Reference Centre for Inherited Sensory Diseases, University Montpellier, CHU Montpellier, F-34000 Montpellier, France;
| | - Marjolaine Willems
- Institute for Neurosciences of Montpellier (INM), University of Montpellier, Inserm, F-34000 Montpellier, France; (I.M.); (M.W.); (V.K.)
- Medical Genetics Department, University of Montpellier, CHU Montpellier, F-34000 Montpellier, France
| | - Valérie Faugère
- Molecular Genetics Laboratory, University of Montpellier, CHU Montpellier, F-34000 Montpellier, France; (L.M.); (D.B.); (C.V.); (V.F.); (C.B.); (M.M.); (J.B.); (M.C.); (M.K.)
| | - Corinne Baudoin
- Molecular Genetics Laboratory, University of Montpellier, CHU Montpellier, F-34000 Montpellier, France; (L.M.); (D.B.); (C.V.); (V.F.); (C.B.); (M.M.); (J.B.); (M.C.); (M.K.)
| | - Melody Moclyn
- Molecular Genetics Laboratory, University of Montpellier, CHU Montpellier, F-34000 Montpellier, France; (L.M.); (D.B.); (C.V.); (V.F.); (C.B.); (M.M.); (J.B.); (M.C.); (M.K.)
| | - Julie Bianchi
- Molecular Genetics Laboratory, University of Montpellier, CHU Montpellier, F-34000 Montpellier, France; (L.M.); (D.B.); (C.V.); (V.F.); (C.B.); (M.M.); (J.B.); (M.C.); (M.K.)
| | - Helene Dollfus
- Reference Center for Rare Affections in Ophthalmology Genetics (CARGO), Institute of Medical Genetics of Alsace, University of Strasbourg, CHU Strasbourg, F-67000 Strasbourg, France;
| | | | - Delphine Dupin-Deguine
- Medical Genetics Department, University of Toulouse, CHU Purpan, F-31000 Toulouse, France;
| | - Dominique Bonneau
- Medical Genetics Department, University of Angers, CHU Angers, F-49000 Angers, France;
| | - Isabelle Drumare
- Vision and Neuro-Ophthalmology Department, University of Lille, CHU Lille, F-59000 Lille, France;
| | - Sylvie Odent
- Clinical Genetics Service, University Hospital, Genetics and Development Institute of Rennes IDGDR, UMR6290 University of Rennes, F-35000 Rennes, France;
| | - Xavier Zanlonghi
- Center of Competence for Rare Diseases, Jules Verne Clinic, F-44000 Nantes, France;
| | - Mireille Claustres
- Molecular Genetics Laboratory, University of Montpellier, CHU Montpellier, F-34000 Montpellier, France; (L.M.); (D.B.); (C.V.); (V.F.); (C.B.); (M.M.); (J.B.); (M.C.); (M.K.)
| | - Michel Koenig
- Molecular Genetics Laboratory, University of Montpellier, CHU Montpellier, F-34000 Montpellier, France; (L.M.); (D.B.); (C.V.); (V.F.); (C.B.); (M.M.); (J.B.); (M.C.); (M.K.)
| | - Vasiliki Kalatzis
- Institute for Neurosciences of Montpellier (INM), University of Montpellier, Inserm, F-34000 Montpellier, France; (I.M.); (M.W.); (V.K.)
| | - Anne-Françoise Roux
- Molecular Genetics Laboratory, University of Montpellier, CHU Montpellier, F-34000 Montpellier, France; (L.M.); (D.B.); (C.V.); (V.F.); (C.B.); (M.M.); (J.B.); (M.C.); (M.K.)
- Institute for Neurosciences of Montpellier (INM), University of Montpellier, Inserm, F-34000 Montpellier, France; (I.M.); (M.W.); (V.K.)
- Correspondence:
| |
Collapse
|
6
|
Sebai F, Rollin A, Mondoly P, Voglimacci-Stephanopoli Q, Dupin-Deguine D, Bieth E, Hocini M, Monteil B, Mandel F, Galinier M, Carrié D, Haïssaguerre M, Sacher F, Maury P. Chest pain in Brugada syndrome: Prevalence, correlations, and prognosis role. Pacing Clin Electrophysiol 2020; 43:365-373. [PMID: 32031268 DOI: 10.1111/pace.13881] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/01/2019] [Revised: 11/12/2019] [Accepted: 11/23/2019] [Indexed: 12/29/2022]
Abstract
BACKGROUND Brugada syndrome (BrS) is sometimes diagnosed because of chest pain. Prevalence and characteristics of such BrS patients are unknown. METHODS A total of 200 BrS probands were retrospectively included. BrS diagnosis made because of chest pain (n = 34, 17%) was compared to the other ones. RESULTS BrS probands with diagnosis because of chest pain had significantly more often smoker habits, increased body mass index, and familial history of coronary artery disease but less frequently previous resuscitated sudden death/syncope or atrial fibrillation. Presence of coronary spasm and familial coronary artery disease were independently associated with BrS diagnosed because of chest pain. They presented more often with spontaneous type 1 ST elevation (59% vs 26%, P = .0004) and higher ST elevation during the episode of chest pain compared to other patients or compared to baseline electrocardiogram after chest pain resumption. ST elevation during chest pain was lower compared to ajmaline test. A total of 20% of them had significant coronary artery disease and four (11%) had coronary spasm, and they experienced more often recurrent chest pain episodes (24% vs 5%, P = .0002). Presence of chest pain at BrS diagnosis was not correlated to future arrhythmic events in univariate analysis. Only previous sudden cardiac death (SD)/syncope and familial SD were still significantly associated with outcome in multivariate analysis. CONCLUSION Chest pain is a common cause for BrS diagnosis, although major part is not apparently explained by ischemic heart disease. Mechanisms leading to chest main remain unknown in the other ones. ST elevation is higher in this situation but does not seem to carry poor prognosis.
Collapse
Affiliation(s)
- Fatiha Sebai
- Department of Cardiology, University Hospital Rangueil, Toulouse, France
| | - Anne Rollin
- Department of Cardiology, University Hospital Rangueil, Toulouse, France
| | - Pierre Mondoly
- Department of Cardiology, University Hospital Rangueil, Toulouse, France
| | | | | | - Eric Bieth
- Department of Genetic, University Hospital Purpan, Toulouse, France
| | - Meleze Hocini
- Department of Cardiology, Bordeaux University Hospital, Bordeaux, France.,LIRYC Institute/INSERM 1045, University of Bordeaux, Bordeaux, France
| | - Benjamin Monteil
- Department of Cardiology, University Hospital Rangueil, Toulouse, France
| | - Franck Mandel
- Department of Cardiology, University Hospital Rangueil, Toulouse, France
| | - Michel Galinier
- Department of Cardiology, University Hospital Rangueil, Toulouse, France
| | - Didier Carrié
- Department of Cardiology, University Hospital Rangueil, Toulouse, France
| | - Michel Haïssaguerre
- Department of Cardiology, Bordeaux University Hospital, Bordeaux, France.,LIRYC Institute/INSERM 1045, University of Bordeaux, Bordeaux, France
| | - Frederic Sacher
- Department of Cardiology, Bordeaux University Hospital, Bordeaux, France.,LIRYC Institute/INSERM 1045, University of Bordeaux, Bordeaux, France
| | - Philippe Maury
- Department of Cardiology, University Hospital Rangueil, Toulouse, France.,Unité Inserm U 1048, Toulouse, France
| |
Collapse
|
7
|
Ader F, De Groote P, Reant P, Dupin-Deguine D, Rambaud C, Khraiche D, Pruny JF, Mathieu Dramard M, Troadec Y, Gouya L, Jeunemaitre X, Van Maldergem L, Villard E, Charron P, Richard P. P1247FLNC pathogenic variants in patients with various cardiomyopathies:prevalence and genotype-phenotype correlations. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz748.0205] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background/Introduction
Pathogenic variants FLNC encoding filamin C have been firstly reported to cause myopathies, and were recently linked to isolated cardiac phenotypes.However, few data on phenotype-genotype correlation are available.
Purpose
Our aim was to estimate the prevalence of FLNC pathogenic variants in cardiomyopathies and to study the relations between phenotype and genotype.
Methods
DNAs from a cohort of 1150 unrelated index-patients with an isolated cardiomyopathy (700 hypertrophic, 300 dilated, 50 restrictive cardiomyopathies, and 100 left ventricle non-compactions) have been sequenced on a custom panel of 52 cardiomyopathy disease-causing genes.
Results
A FLNC pathogenic variant was identified in 28 patients corresponding to a prevalence ranging from 1 to 8% depending on the cardiomyopathy subtypes. Truncating variants were always identified in patients with dilated cardiomyopathy, while missense or in-frame variants were found in other phenotypes. This work reported for the first time a left ventricular non-compaction associated with FLNC pathogenic variant.
In the cohort, nine patients (32%) were implanted with an automatic defibrillator. In 7 families (25%), history of sudden cardiac death (SCD) before 50 years was reported. A personal or family history of sudden cardiac death (SCD) was significantly higher in patients with truncating variants than in patients carrying missense variants (p=0.01). Four patients died of cardiac cause including 3 from SCD and 1 from heart failure.
Conclusion
This work highlights the role of FLNC in cardiomyopathies. A correlation between the type of the variant and the cardiomyopathy subtype was observed as well as with SCD risk. These new data should be taken into consideration for patient's management and primary prevention of sudden cardiac death.
Acknowledgement/Funding
La ligue contre la Cardiomyopathie
Collapse
Affiliation(s)
- F Ader
- Hospital Pitie-Salpetriere, Paris, France
| | | | - P Reant
- Hospital Haut Leveque, Bordeaux-Pessac, France
| | | | - C Rambaud
- Hopital Raymond Poincare, Garches, France
| | | | - J F Pruny
- Hospital Pitie-Salpetriere, Paris, France
| | | | - Y Troadec
- University Hospital of Caen, Caen, France
| | - L Gouya
- Hospital Bichat-Claude Bernard, Paris, France
| | | | | | | | - P Charron
- Hospital Pitie-Salpetriere, Paris, France
| | - P Richard
- Hospital Pitie-Salpetriere, Paris, France
| |
Collapse
|
8
|
Ader F, De Groote P, Réant P, Rooryck-Thambo C, Dupin-Deguine D, Rambaud C, Khraiche D, Perret C, Pruny JF, Mathieu-Dramard M, Gérard M, Troadec Y, Gouya L, Jeunemaitre X, Van Maldergem L, Hagège A, Villard E, Charron P, Richard P. FLNC pathogenic variants in patients with cardiomyopathies: Prevalence and genotype-phenotype correlations. Clin Genet 2019; 96:317-329. [PMID: 31245841 DOI: 10.1111/cge.13594] [Citation(s) in RCA: 49] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2019] [Revised: 05/14/2019] [Accepted: 05/15/2019] [Indexed: 01/17/2023]
Abstract
Pathogenic variants in FLNC encoding filamin C have been firstly reported to cause myopathies, and were recently linked to isolated cardiac phenotypes. Our aim was to estimate the prevalence of FLNC pathogenic variants in subtypes of cardiomyopathies and to study the relations between phenotype and genotype. DNAs from a cohort of 1150 unrelated index-patients with isolated cardiomyopathy (700 hypertrophic, 300 dilated, 50 restrictive cardiomyopathies, and 100 left ventricle non-compactions) have been sequenced on a custom panel of 51 cardiomyopathy disease-causing genes. An FLNC pathogenic variant was identified in 28 patients corresponding to a prevalence ranging from 1% to 8% depending on the cardiomyopathy subtype. Truncating variants were always identified in patients with dilated cardiomyopathy, while missense or in-frame indel variants were found in other phenotypes. A personal or family history of sudden cardiac death (SCD) was significantly higher in patients with truncating variants than in patients carrying missense variants (P = .01). This work reported the first observation of a left ventricular non-compaction associated with a unique probably causal variant in FLNC which highlights the role of FLNC in cardiomyopathies. A correlation between the nature of the variant and the cardiomyopathy subtype was observed as well as with SCD risk.
Collapse
Affiliation(s)
- Flavie Ader
- APHP, UF Cardiogénétique et Myogénétique Moléculaire et Cellulaire, Service de Biochimie Métabolique, Hôpitaux Universitaires de la Pitié- Salpêtrière- Charles Foix, Paris, France.,Sorbonne Université, UPMC Univ., INSERM, UMR_S 1166 and ICAN Institute for Cardiometabolism and Nutrition, Paris, France.,Université Paris Descartes, Faculté de Pharmacie, Paris, France
| | - Pascal De Groote
- Pôle Cardio-Vasculaire et Pulmonaire, CHRU de Lille - Hôpital Albert Calmette, Lille, France
| | - Patricia Réant
- Service de Cardiologie, CHU de Bordeaux, Université de Bordeaux, Paris, France
| | | | - Delphine Dupin-Deguine
- Service de génétique médicale, et service d'otoneurochirurgie, CHU de Toulouse - Hôpital Purpan, Toulouse, France
| | - Caroline Rambaud
- APHP, Service Médecine Légale, Hôpital Raymond Poincaré, Garches, France
| | - Diala Khraiche
- APHP, Service de Cardiologie, Hôpital Necker, Paris, France
| | - Claire Perret
- Sorbonne Université, UPMC Univ., INSERM, UMR_S 1166 and ICAN Institute for Cardiometabolism and Nutrition, Paris, France
| | - Jean François Pruny
- APHP, Centre de référence pour les maladies cardiaques héréditaires, Hôpitaux Universitaires Pitié-Salpêtrière, Paris, France
| | | | - Marion Gérard
- CHU Caen, Service de Génétique Médicale, Caen, France
| | - Yann Troadec
- CHU Caen, Service de Génétique Médicale, Caen, France
| | - Laurent Gouya
- APHP, Service de Génétique Médicale, CHU Bichat-Claude Bernard, Paris, France
| | - Xavier Jeunemaitre
- APHP, Service de génétique, Hôpital Européen Georges Pompidou, Paris, France
| | | | - Albert Hagège
- APHP, Service de Cardiologie, Hôpital Européen Georges Pompidou, Paris, France
| | - Eric Villard
- Sorbonne Université, UPMC Univ., INSERM, UMR_S 1166 and ICAN Institute for Cardiometabolism and Nutrition, Paris, France
| | - Philippe Charron
- Sorbonne Université, UPMC Univ., INSERM, UMR_S 1166 and ICAN Institute for Cardiometabolism and Nutrition, Paris, France.,APHP, Centre de référence pour les maladies cardiaques héréditaires, Hôpitaux Universitaires Pitié-Salpêtrière, Paris, France
| | - Pascale Richard
- APHP, UF Cardiogénétique et Myogénétique Moléculaire et Cellulaire, Service de Biochimie Métabolique, Hôpitaux Universitaires de la Pitié- Salpêtrière- Charles Foix, Paris, France.,Sorbonne Université, UPMC Univ., INSERM, UMR_S 1166 and ICAN Institute for Cardiometabolism and Nutrition, Paris, France.,APHP, Centre de référence pour les maladies cardiaques héréditaires, Hôpitaux Universitaires Pitié-Salpêtrière, Paris, France
| |
Collapse
|
9
|
Isidor B, Julia S, Saugier-Veber P, Weil-Dubuc PL, Bézieau S, Bieth E, Bonnefont JP, Munnich A, Bourdeaut F, Bourgain C, Chassaing N, Corradini N, Haye D, Plaisancie J, Dupin-Deguine D, Calvas P, Mignot C, Cogné B, Manouvrier S, Pasquier L, Héron D, Boycott KM, Turrini M, Vears DF, Nizon M, Vincent M. Searching for secondary findings: considering actionability and preserving the right not to know. Eur J Hum Genet 2019; 27:1481-1484. [PMID: 31186543 DOI: 10.1038/s41431-019-0438-x] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2019] [Revised: 05/04/2019] [Accepted: 05/21/2019] [Indexed: 11/10/2022] Open
Affiliation(s)
- Bertrand Isidor
- Service de génétique médicale, CHU Nantes, 9 quai Moncousu, 44093, Nantes, France.
| | - Sophie Julia
- Service de génétique médicale, Hôpital Purpan, Centre Hospitalier Universitaire, 31059, Toulouse, France
| | - Pascale Saugier-Veber
- Normandie Univ, UNIROUEN, Inserm U1245, Normandy Centre for Genomic and Personalized Medicine, 76000, Rouen, France.,Department of Genetics, Rouen University Hospital, Normandy Centre for Genomic and Personalized Medicine, 76000, Rouen, France
| | - Paul-Loup Weil-Dubuc
- Espace éthique Ile-de-France, Laboratoire d'excellence Distalz, Université Paris-Sud, Paris-Saclay, France
| | - Stéphane Bézieau
- Service de génétique médicale, CHU Nantes, 9 quai Moncousu, 44093, Nantes, France
| | - Eric Bieth
- Service de génétique médicale, Hôpital Purpan, Centre Hospitalier Universitaire, 31059, Toulouse, France
| | - Jean-Paul Bonnefont
- Service de génétique médicale, Hôpital Necker-Enfants Malades, AP-HP, Paris, France
| | - Arnold Munnich
- Service de génétique médicale, Hôpital Necker-Enfants Malades, AP-HP, Paris, France
| | | | - Catherine Bourgain
- Cermes3 (Centre de recherche médecine, sciences, santé, santé mentale, société), Inserm U988, site CNRS, 7 rue Guy Môquet, 94801, Villejuif, France
| | - Nicolas Chassaing
- Service de génétique médicale, Hôpital Purpan, Centre Hospitalier Universitaire, 31059, Toulouse, France
| | - Nadège Corradini
- Institut d'hémato-oncologie pédiatrique, Centre Léon Bérard, Lyon, France
| | - Damien Haye
- APHP, Département de Génétique, Groupe Hospitalier Pitié Salpêtrière, Paris, France
| | - Julie Plaisancie
- Service de génétique médicale, Hôpital Purpan, Centre Hospitalier Universitaire, 31059, Toulouse, France
| | - Delphine Dupin-Deguine
- Service de génétique médicale, Hôpital Purpan, Centre Hospitalier Universitaire, 31059, Toulouse, France.,Service d'otoneurologie et ORL pédiatrique, Hôpital Purpan, Centre Hospitalier Universitaire, 31059, Toulouse, France
| | - Patrick Calvas
- Service de génétique médicale, Hôpital Purpan, Centre Hospitalier Universitaire, 31059, Toulouse, France
| | - Cyril Mignot
- APHP, Département de Génétique, Groupe Hospitalier Pitié Salpêtrière, Paris, France
| | - Benjamin Cogné
- Service de génétique médicale, CHU Nantes, 9 quai Moncousu, 44093, Nantes, France
| | - Sylvie Manouvrier
- Clinique de génétique, CHU de Lille, 59000, Lille, France.,EA7364 Faculté de Médecine Université de Lille, 59000, Lille, France
| | - Laurent Pasquier
- CHU Rennes, Service de Génétique Clinique, 16 Boulevard de Bulgarie, 35203, Rennes, France
| | - Delphine Héron
- APHP, Département de Génétique, Groupe Hospitalier Pitié Salpêtrière, Paris, France
| | - Kym M Boycott
- Children's Hospital of Eastern Ontario Research Institute, University of Ottawa, Ontario, Canada
| | - Mauro Turrini
- DCS- Droit et Changement Social Université de Nantes, Nantes, France
| | - Danya F Vears
- Department of Public Health and Primary Care, Center for Biomedical Ethics and Law, KU Leuven, Belgium.,Leuven Institute for Human Genetics and Society, Leuven, Belgium.,Melbourne Law School, University of Melbourne, Carlton, Australia.,Murdoch Children's Research Institute, The Royal Children's Hospital, Parkville, Australia
| | - Mathilde Nizon
- Service de génétique médicale, CHU Nantes, 9 quai Moncousu, 44093, Nantes, France
| | - Marie Vincent
- Service de génétique médicale, CHU Nantes, 9 quai Moncousu, 44093, Nantes, France.
| |
Collapse
|
10
|
Baux D, Vaché C, Blanchet C, Willems M, Baudoin C, Moclyn M, Faugère V, Touraine R, Isidor B, Dupin-Deguine D, Nizon M, Vincent M, Mercier S, Calais C, García-García G, Azher Z, Lambert L, Perdomo-Trujillo Y, Giuliano F, Claustres M, Koenig M, Mondain M, Roux AF. Combined genetic approaches yield a 48% diagnostic rate in a large cohort of French hearing-impaired patients. Sci Rep 2017; 7:16783. [PMID: 29196752 PMCID: PMC5711943 DOI: 10.1038/s41598-017-16846-9] [Citation(s) in RCA: 43] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2017] [Accepted: 11/17/2017] [Indexed: 11/22/2022] Open
Abstract
Hearing loss is the most common sensory disorder and because of its high genetic heterogeneity, implementation of Massively Parallel Sequencing (MPS) in diagnostic laboratories is greatly improving the possibilities of offering optimal care to patients. We present the results of a two-year period of molecular diagnosis that included 207 French families referred for non-syndromic hearing loss. Our multi-step strategy involved (i) DFNB1 locus analysis, (ii) MPS of 74 genes, and (iii) additional approaches including Copy Number Variations, in silico analyses, minigene studies coupled when appropriate with complete gene sequencing, and a specific assay for STRC. This comprehensive screening yielded an overall diagnostic rate of 48%, equally distributed between DFNB1 (24%) and the other genes (24%). Pathogenic genotypes were identified in 19 different genes, with a high prevalence of GJB2, STRC, MYO15A, OTOF, TMC1, MYO7A and USH2A. Involvement of an Usher gene was reported in 16% of the genotyped cohort. Four de novo variants were identified. This study highlights the need to develop several molecular approaches for efficient molecular diagnosis of hearing loss, as this is crucial for genetic counselling, audiological rehabilitation and the detection of syndromic forms.
Collapse
Affiliation(s)
- D Baux
- Laboratoire de Génétique Moléculaire, CHU Montpellier, Montpellier, France
| | - C Vaché
- Laboratoire de Génétique Moléculaire, CHU Montpellier, Montpellier, France
| | - C Blanchet
- Service ORL, CHU Montpellier, Montpellier, France.,Centre National de Référence Maladies Rares "Affections Sensorielles Génétiques", CHU Montpellier, Montpellier, France
| | - M Willems
- Génétique Médicale, CHU Montpellier, Montpellier, France
| | - C Baudoin
- Laboratoire de Génétique Moléculaire, CHU Montpellier, Montpellier, France
| | - M Moclyn
- Laboratoire de Génétique Moléculaire, CHU Montpellier, Montpellier, France
| | - V Faugère
- Laboratoire de Génétique Moléculaire, CHU Montpellier, Montpellier, France
| | - R Touraine
- Service de Génétique, CHU-Hôpital Nord, Saint-Etienne, France
| | - B Isidor
- Service de Génétique Médicale, CHU Nantes, Nantes, France
| | - D Dupin-Deguine
- Service de Génétique Médicale, CHU Toulouse, Toulouse, France.,Service d'ORL, Otoneurologie et ORL pédiatrique CHU Toulouse, Toulouse, France
| | - M Nizon
- Service de Génétique Médicale, CHU Nantes, Nantes, France
| | - M Vincent
- Service de Génétique Médicale, CHU Nantes, Nantes, France
| | - S Mercier
- Service de Génétique Médicale, CHU Nantes, Nantes, France
| | - C Calais
- Service d'ORL, CHU Nantes, Nantes, France
| | - G García-García
- Laboratoire de Génétique de Maladies Rares (LGMR) EA7402, Université de Montpellier, Montpellier, France
| | - Z Azher
- Laboratoire de Génétique de Maladies Rares (LGMR) EA7402, Université de Montpellier, Montpellier, France
| | - L Lambert
- Génétique Médicale, Centre de Compétence des Surdités Génétiques, site constitutif du Centre de Référence des Anomalies du Développement et Syndromes Malformatifs de l'Est, CHRU Nancy, Nancy, France
| | - Y Perdomo-Trujillo
- Service de Génétique Médicale, Centre de Référence pour les Affections Rares en Génétique Ophtalmologique (CARGO), Hôpital Civil, Strasbourg, France
| | - F Giuliano
- Service de Génétique Médicale, CHU Nice, Nice, France
| | - M Claustres
- Laboratoire de Génétique Moléculaire, CHU Montpellier, Montpellier, France.,Laboratoire de Génétique de Maladies Rares (LGMR) EA7402, Université de Montpellier, Montpellier, France
| | - M Koenig
- Laboratoire de Génétique Moléculaire, CHU Montpellier, Montpellier, France.,Laboratoire de Génétique de Maladies Rares (LGMR) EA7402, Université de Montpellier, Montpellier, France
| | - M Mondain
- Service ORL, CHU Montpellier, Montpellier, France.,Centre National de Référence Maladies Rares "Affections Sensorielles Génétiques", CHU Montpellier, Montpellier, France
| | - A F Roux
- Laboratoire de Génétique Moléculaire, CHU Montpellier, Montpellier, France. .,Laboratoire de Génétique de Maladies Rares (LGMR) EA7402, Université de Montpellier, Montpellier, France.
| |
Collapse
|
11
|
Barat-Houari M, Dumont B, Fabre A, Them FT, Alembik Y, Alessandri JL, Amiel J, Audebert S, Baumann-Morel C, Blanchet P, Bieth E, Brechard M, Busa T, Calvas P, Capri Y, Cartault F, Chassaing N, Ciorca V, Coubes C, David A, Delezoide AL, Dupin-Deguine D, El Chehadeh S, Faivre L, Giuliano F, Goldenberg A, Isidor B, Jacquemont ML, Julia S, Kaplan J, Lacombe D, Lebrun M, Marlin S, Martin-Coignard D, Martinovic J, Masurel A, Melki J, Mozelle-Nivoix M, Nguyen K, Odent S, Philip N, Pinson L, Plessis G, Quélin C, Shaeffer E, Sigaudy S, Thauvin C, Till M, Touraine R, Vigneron J, Baujat G, Cormier-Daire V, Le Merrer M, Geneviève D, Touitou I. The expanding spectrum of COL2A1 gene variants IN 136 patients with a skeletal dysplasia phenotype. Eur J Hum Genet 2015; 24:992-1000. [PMID: 26626311 DOI: 10.1038/ejhg.2015.250] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2015] [Revised: 08/21/2015] [Accepted: 10/29/2015] [Indexed: 11/09/2022] Open
Abstract
Heterozygous COL2A1 variants cause a wide spectrum of skeletal dysplasia termed type II collagenopathies. We assessed the impact of this gene in our French series. A decision tree was applied to select 136 probands (71 Stickler cases, 21 Spondyloepiphyseal dysplasia congenita cases, 11 Kniest dysplasia cases, and 34 other dysplasia cases) before molecular diagnosis by Sanger sequencing. We identified 66 different variants among the 71 positive patients. Among those patients, 18 belonged to multiplex families and 53 were sporadic. Most variants (38/44, 86%) were located in the triple helical domain of the collagen chain and glycine substitutions were mainly observed in severe phenotypes, whereas arginine to cysteine changes were more often encountered in moderate phenotypes. This series of skeletal dysplasia is one of the largest reported so far, adding 44 novel variants (15%) to published data. We have confirmed that about half of our Stickler patients (46%) carried a COL2A1 variant, and that the molecular spectrum was different across the phenotypes. To further address the question of genotype-phenotype correlation, we plan to screen our patients for other candidate genes using a targeted next-generation sequencing approach.
Collapse
Affiliation(s)
- Mouna Barat-Houari
- Laboratoire de génétique des maladies rares et auto-inflammatoires, CHRU, Montpellier, France.,Génétique des Maladies Auto-inflammatoires et des Ostéo-arthropathies chroniques, INSERM U1183, Montpellier, France
| | - Bruno Dumont
- Laboratoire de génétique des maladies rares et auto-inflammatoires, CHRU, Montpellier, France
| | - Aurélie Fabre
- Laboratoire de génétique des maladies rares et auto-inflammatoires, CHRU, Montpellier, France
| | - Frédéric Tm Them
- Département de Génétique Médicale, Centre de référence des anomalies du développement, Centre de compétence des Maladies Osseuses Constitutionnelles, CHRU, Montpellier, France
| | - Yves Alembik
- Génétique Médicale, Hôpital Hautepierre, Strasbourg, France
| | | | - Jeanne Amiel
- Département de Génétique et INSERM U781, Université Paris Descartes-Sorbonne Paris Cité, Fondation Imagine, Hôpital Necker-Enfants malades, AP-HP, Paris, France
| | - Séverine Audebert
- Pédiatrie et Génétique Médicale, CHU de Brest - Hôpital Auguste Morvan, Brest, France
| | | | - Patricia Blanchet
- Département de Génétique Médicale, Centre de référence des anomalies du développement, Centre de compétence des Maladies Osseuses Constitutionnelles, CHRU, Montpellier, France
| | - Eric Bieth
- Département de Génétique Médicale, institut Fédératif de Biologie, Hôpital Purpan, Toulouse, France
| | - Marie Brechard
- Unité de consultations externes, Hôpital Saint Joseph, Marseille, France
| | - Tiffany Busa
- Unité de Génétique Clinique, Hôpital d'Enfants de la Timone, Marseille, France
| | - Patrick Calvas
- Département de Génétique Médicale, institut Fédératif de Biologie, Hôpital Purpan, Toulouse, France
| | - Yline Capri
- Département de Génétique, Hôpital Robert Debré, Paris, France
| | - François Cartault
- Service de Génétique, CHU Félix Guyon, Saint-Denis, La Réunion, France
| | - Nicolas Chassaing
- Département de Génétique Médicale, institut Fédératif de Biologie, Hôpital Purpan, Toulouse, France
| | | | - Christine Coubes
- Département de Génétique Médicale, Centre de référence des anomalies du développement, Centre de compétence des Maladies Osseuses Constitutionnelles, CHRU, Montpellier, France
| | | | | | - Delphine Dupin-Deguine
- Département de Génétique Médicale, institut Fédératif de Biologie, Hôpital Purpan, Toulouse, France
| | | | - Laurence Faivre
- Centre de Génétique, CHU Dijon - Hôpital d'Enfants, Dijon, France
| | - Fabienne Giuliano
- Département de Génétique Médicale, CHU de Nice - Hôpital de l'Archet II, Nice, France
| | - Alice Goldenberg
- Unité de Génétique Clinique, CHU de Rouen - Hôpital Charles Nicolle, Rouen, France
| | | | | | - Sophie Julia
- Département de Génétique Médicale, institut Fédératif de Biologie, Hôpital Purpan, Toulouse, France
| | - Josseline Kaplan
- Département de Génétique et INSERM U781, Université Paris Descartes-Sorbonne Paris Cité, Fondation Imagine, Hôpital Necker-Enfants malades, AP-HP, Paris, France
| | - Didier Lacombe
- Département de Génétique Médicale, Groupe Hospitalier Pellegrin, Bordeaux, France
| | - Marine Lebrun
- Génétique Clinique, Chromosomique et Moléculaire, CHU Hôpital Nord, St Pirest en Jarez, France
| | - Sandrine Marlin
- Génétique et Embryologie Médicales, Hôpital Armand Trousseau, Paris, France
| | | | | | - Alice Masurel
- Centre de Génétique, CHU Dijon - Hôpital d'Enfants, Dijon, France
| | - Judith Melki
- Pôle Neurosciences Tête et Cou (NTC), GHU Paris-Sud - Hôpital de Bicêtre, Le Kremlin Bicêtre, France
| | | | - Karine Nguyen
- Unité de Génétique Clinique, Hôpital d'Enfants de la Timone, Marseille, France
| | - Sylvie Odent
- Service de Génétique Clinique, numéro 9, CHU, Rennes, France
| | - Nicole Philip
- Unité de Génétique Clinique, Hôpital d'Enfants de la Timone, Marseille, France
| | - Lucile Pinson
- Département de Génétique Médicale, Centre de référence des anomalies du développement, Centre de compétence des Maladies Osseuses Constitutionnelles, CHRU, Montpellier, France
| | | | - Chloé Quélin
- Service de Génétique Clinique, numéro 9, CHU, Rennes, France
| | - Elise Shaeffer
- Génétique Médicale, Hôpital Hautepierre, Strasbourg, France
| | - Sabine Sigaudy
- Unité de Génétique Clinique, Hôpital d'Enfants de la Timone, Marseille, France
| | - Christel Thauvin
- Centre de Génétique, CHU Dijon - Hôpital d'Enfants, Dijon, France
| | - Marianne Till
- Service de Cytogénétique Constitutionnelle, Groupement Hospitalier Est - Hôpitaux de Lyon, Bron, France
| | - Renaud Touraine
- Génétique Clinique, Chromosomique et Moléculaire, CHU Hôpital Nord, St Pirest en Jarez, France
| | | | - Geneviève Baujat
- Département de Génétique et INSERM U781, Université Paris Descartes-Sorbonne Paris Cité, Fondation Imagine, Hôpital Necker-Enfants malades, AP-HP, Paris, France
| | - Valérie Cormier-Daire
- Département de Génétique et INSERM U781, Université Paris Descartes-Sorbonne Paris Cité, Fondation Imagine, Hôpital Necker-Enfants malades, AP-HP, Paris, France
| | - Martine Le Merrer
- Département de Génétique et INSERM U781, Université Paris Descartes-Sorbonne Paris Cité, Fondation Imagine, Hôpital Necker-Enfants malades, AP-HP, Paris, France
| | - David Geneviève
- Département de Génétique Médicale, Centre de référence des anomalies du développement, Centre de compétence des Maladies Osseuses Constitutionnelles, CHRU, Montpellier, France.,Génétique des Maladies Auto-inflammatoires et des Ostéo-arthropathies chroniques, INSERM U1183, Montpellier, France.,Université de Montpellier, Montpellier, France
| | - Isabelle Touitou
- Laboratoire de génétique des maladies rares et auto-inflammatoires, CHRU, Montpellier, France.,Génétique des Maladies Auto-inflammatoires et des Ostéo-arthropathies chroniques, INSERM U1183, Montpellier, France.,Université de Montpellier, Montpellier, France
| |
Collapse
|
12
|
Pingault V, Bodereau V, Baral V, Marcos S, Watanabe Y, Chaoui A, Fouveaut C, Leroy C, Vérier-Mine O, Francannet C, Dupin-Deguine D, Archambeaud F, Kurtz FJ, Young J, Bertherat J, Marlin S, Goossens M, Hardelin JP, Dodé C, Bondurand N. Loss-of-function mutations in SOX10 cause Kallmann syndrome with deafness. Am J Hum Genet 2013; 92:707-24. [PMID: 23643381 DOI: 10.1016/j.ajhg.2013.03.024] [Citation(s) in RCA: 137] [Impact Index Per Article: 12.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2012] [Revised: 02/25/2013] [Accepted: 03/29/2013] [Indexed: 12/11/2022] Open
Abstract
Transcription factor SOX10 plays a role in the maintenance of progenitor cell multipotency, lineage specification, and cell differentiation and is a major actor in the development of the neural crest. It has been implicated in Waardenburg syndrome (WS), a rare disorder characterized by the association between pigmentation abnormalities and deafness, but SOX10 mutations cause a variable phenotype that spreads over the initial limits of the syndrome definition. On the basis of recent findings of olfactory-bulb agenesis in WS individuals, we suspected SOX10 was also involved in Kallmann syndrome (KS). KS is defined by the association between anosmia and hypogonadotropic hypogonadism due to incomplete migration of neuroendocrine gonadotropin-releasing hormone (GnRH) cells along the olfactory, vomeronasal, and terminal nerves. Mutations in any of the nine genes identified to date account for only 30% of the KS cases. KS can be either isolated or associated with a variety of other symptoms, including deafness. This study reports SOX10 loss-of-function mutations in approximately one-third of KS individuals with deafness, indicating a substantial involvement in this clinical condition. Study of SOX10-null mutant mice revealed a developmental role of SOX10 in a subpopulation of glial cells called olfactory ensheathing cells. These mice indeed showed an almost complete absence of these cells along the olfactory nerve pathway, as well as defasciculation and misrouting of the nerve fibers, impaired migration of GnRH cells, and disorganization of the olfactory nerve layer of the olfactory bulbs.
Collapse
Affiliation(s)
- Veronique Pingault
- Equipe 11, Institut National de la Santé et de la Recherche Médicale Unité 955, 94000 Créteil, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Ghedira ES, Dupin-Deguine D, Duffilot D, Lemetayer N, Faubert E, Pissard S. A Second Observation of the Rare Frameshift Mutation in the β-Globin Gene: Codon 46 (+A) (Hbb:c.138_139insA). Hemoglobin 2011; 35:157-61. [DOI: 10.3109/03630269.2011.557460] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|